An open-label safety and pharmacokinetics study of duloxetine in pediatric patients with major depression

Journal of Child and Adolescent Psychopharmacology

Volumn 22, Issue 1, 2012, Pages 48-55

  Prakash, Apurva ^a   Lobo, Evelyn ^a   Kratochvil, Christopher J ^b   Tamura, Roy N ^a   Pangallo, Beth A ^a   Bullok, Kristin E ^a   Quinlan, Tonya ^a   Emslie, Graham J ^c   March, John S ^d  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE;

ADOLESCENT; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CHILD; CLINICAL GLOBAL IMPRESSION SCALE; CREATININE CLEARANCE; DECREASED APPETITE; DIZZINESS; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; RATING SCALE; RHINOPHARYNGITIS; RHINORRHEA; SCHOOL CHILD; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; SUICIDE ATTEMPT; TREATMENT DURATION; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VIRAL GASTROENTERITIS; VOMITING; XEROSTOMIA;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; BLOOD PRESSURE; CHILD; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; SUICIDAL IDEATION; THIOPHENES; TREATMENT OUTCOME;

EID: 84857334131     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2011.0072     Document Type: Article

References (18)

1. American Psychiatric Association : Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association: 2000.
2. Atuah KN, Hughes D, Pirmohamed M: Clinical pharmacology: Special safety considerations in drug development and pharmacovigilance. Drug Saf 27:535-554, 2004. (Pubitemid 38822574)
3. Beal SL, Sheiner LB: NONMEM Users Guide-Part VII** Conditional Estimation Methods. San Francisco, CA: Regents of the University of California; 1992.
4. Bymaster FP, Lee TC, Knadler MP, Detke MJ, Iyengar S: The dual transporter inhibitor duloxetine: A review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des 11:1475-1493, 2005 (Pubitemid 40691447)
5. Cymbalta Full Prescribing Information. Available at www.Cymbalta .com. Accessed September 8, 2011.
6. Derby MA, Zhang L, Chappell JC, Gonzales CR, Callaghan JT, Leibowitz M, Ereshefsky L, Hoelscher D, Leese PT, Mitchell MI: The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate. J Cardiovasc Pharmacol 49:384-393, 2007. (Pubitemid 47000313)
7. Findling RL, Mc Namara NK, Stansbrey RJ, Feeny NC, Young CM, Peric FV, Youngstrom EA: The relevance of pharmacokinetic studies in designing efficacy trials in juvenile major depression. J Child Adolesc Psychopharmacol 16:131-145, 2006.
8. Guy W: ECDEU Assessment Manual for Psychopharmacology (NIMH). Rockville, MD: National Institute of Mental Health, Psychopharmacology Research Branch; 1976.
9. Hammad TA, Laughren T, Racoosin J: Suicidality in pediatric pa-tients treated with antidepressant drugs. Arch Gen Psychiatry 63:332-339, 2006. (Pubitemid 43345358)
10. Hudson JI, Wohlreich MM, Kajdasz DK, Mallinckrodt CH, Watkin JG, Martynov OV: Safety and tolerability of duloxetine in the treatment of major depressive disorder: Analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharma-col 20:327-341, 2005. (Pubitemid 41093935)
11. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N: Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980-988, 1997. (Pubitemid 27272932)
12. Lobo ED, Bergstrom RF, Reddy S, Quinlan T, Chappell J, Hong Q, Ring B, Knadler MP: In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. Clin Pharmacokinet 47:191-202, 2008.
13. Lobo ED, Heathman M, Kuan HY, Reddy S, O'Brien L, Gonzales C, Skinner M, Knadler MP: Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: Ana-lysis of a single-dose phase I study and pooled steady-state data from phase II/III trials. Clin Pharmacokinet 49:311-321, 2010.
14. Lobo ED, Quinlan T, O'Brien L, Knadler MP, Heathman M: Population pharmacokinetics of orally administered duloxetine in patients: Implications for dosing recommendation. Clin Pharma-cokinet 48:189-197, 2009.
15. National High Blood Pressure Education Program Working Group. The fourth report on the diagnosis, evaluation, and treatment ofhigh blood pressure in children and adolescents. Pediatrics 114:555-576, 2004.
16. Posner K: State of the science: Measurement of suicidal adverse events and the Columbia Suicide Severity Rating Scale. Presented at the NCDEU 47th Annual Meeting, Boca Raton, FL, 2007.
17. Poznanski EO, Grossman JA, Buchsbaum Y, Banegas M, Freeman L, Gibbons R: Preliminary studies of the reliability and validity of the children's depression rating scale. J Am Acad Child Psychiatry 23:191-197, 1984. (Pubitemid 14066113)
18. Skinner MH, Kuan HY, Pan A, Sathirakul K, Knadler MP, Gonzales CR, Yeo KP, Reddy S, Lim M, Ayan-Oshodi M, Wise SD: Dulox-etine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther 73:170-177, 2003. (Pubitemid 36269668)